ERBB2 and gastric cancer: A Phase II–III study of KN026 combined with CTH versus CTH alone in the second-line treatment of HER2-positive advanced or metastatic GC has been launched recently (NCT05427383) to further investigate the potential of KN026 in combination therapy [165,169].